About
Scinus Group develops an automated benchtop bioreactor platform, Osilaris™, for scalable, cost-efficient manufacturing and expansion of cell therapies including MSCs, T-cells, HEK, and iPSCs.
Explore Scinus Group's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.